Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
Edward G. Neilan from NORD discusses critical efforts to speed up therapy development for rare diseases lacking treatments ...
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The hemophilia clinical trial analysis report delivers important insights ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today ...
Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence ...
Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical ...
Advancements in Interoperability: Achieving Anatomic Pathology Reports That Adhere to International Standards and Are Both Human-Readable and Readily Computable Favorable, intermediate, and adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results